Filing Analysis
Officer Departure
Filed Apr 02, 2026
MEDIUM
Coya Therapeutics announced the resignation of Dr. Howard Berman from his roles as Executive Chairman and Board member, effective April 1, 2026. The company simultaneously appointed Mark H. Pavao as an independent director to fill the vacancy and entered into a separation agreement with Dr. Berman.
Key Facts
- Dr. Howard Berman resigned as Executive Chairman and from the Board effective April 1, 2026.
- Mark H. Pavao was appointed as a Class III independent director effective April 1, 2026, with a term expiring in 2028.
- Dr. Berman will receive a prorated 2026 annual bonus at 100% of target and COBRA premium coverage through March 31, 2027.
- Dr. Berman's unvested stock options will continue to vest for 12 months post-separation, with a two-year exercise window for all vested options.
- New director Mark H. Pavao was granted 10,000 stock options vesting on the one-year anniversary of the grant.
Regulation FD Disclosure
Filed Mar 16, 2026
LOW
Coya Therapeutics, Inc. issued a press release on March 16, 2026, disclosing its financial results for the fiscal year ended December 31, 2025. The filing is a routine disclosure of operations and financial condition as required by Item 2.02.
Key Facts
- Report date: March 16, 2026
- Fiscal year covered: Ended December 31, 2025
- Item 2.02: Results of Operations and Financial Condition disclosed
- Exhibit 99.1: Press release dated March 16, 2026, furnished with the filing
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.